Perceptions of telehealth in real-world oncological care: An exploration of matched patient- and clinician-reported acceptability data from an Australian cancer centre

Anna Collins1 | Sue-Anne McLachlan1,2 | Leeanne Pasanen1 | Olivia Wawryk1 | Jennifer Philip1,3

1Department of Medicine, St Vincent’s Hospital Melbourne, University of Melbourne, Melbourne, Victoria, Australia
2Medical Oncology, St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia
3Parkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Correspondence
Jennifer Philip, Department of Medicine, St Vincent’s Hospital, University of Melbourne PO BOX 2900, Fitzroy, VIC 3065, Australia. Email: jphilip@unimelb.edu.au

Funding information
Funding for this study was provided through a philanthropic grant from Australian Unity, Joyce Granger Sub-Fund. AC is funded by an Emerging Leadership Investigator Grant awarded by the National Health and Medical Research Council (CIA: A.C., NHMRC GNT173054). The contents of the published material are solely the responsibility of the individual authors and do not reflect the views of the NHMRC, who had no role in the study conduct or interpretation of the results.

Abstract

Background: Prior to 2020, the use of telehealth in cancer care was limited, but COVID-19 necessitated its rapid and widespread adoption into routine care delivery. This study aimed to evaluate perceptions of telehealth through a dyadic exploration of matched cancer patient- and clinician-reported acceptability data and to explore factors that may predict greater suitability for telehealth.

Methods: A prospective, cross-sectional, exploratory survey study assessed (matched) patient- and clinician-reported perceptions of telehealth consultations occurring at a metropolitan, tertiary-based cancer centre in Victoria, Australia.

Results: One-hundred and fifty-five matched patient- and clinician-reported data were included. High rates of acceptability with telehealth were reported by patients (93%) and clinicians (91%), who mostly shared concordant views (86%). Factors significantly associated with increased acceptability for telehealth, included, for clinicians, greater familiarity with the patient (OR 8.20, 95% CI: 1.50–45.06, p = 0.02), and younger patient age (OR 1.06, 95% CI: 0.99–1.13, p = 0.05), and for patients was earlier stage disease (≤stage III) (OR 5.29, 95% CI: 1.08–25.82, p = 0.04). Lower acceptability for telehealth according to clinicians was associated with poorer patient performance status (OR 0.04, 95% CI 1.00–1.08, p = 0.04) and for patients with the need for an interpreter (OR 0.06, 95% CI: 0.008–0.51, p = 0.009).

Conclusion: While overall telehealth is acceptable in cancer care, our findings raise important implications for future service development, notably that it may be less optimal for patients with higher complexity of need—including those with more advanced disease, poorer performance status, those less well known to treating clinicians and those identified to have additional language barriers.

KEYWORDS
care delivery, oncologists, patients, perceptions, prospective cross-sectional survey, telehealth
1 | INTRODUCTION

Oncological clinical practice guidelines, both in Australia and internationally, identify the potential role of telehealth in expanding service capabilities and enabling greater equity of access to specialist cancer care, especially for people living outside of metropolitan settings. Despite this, historically telehealth has rarely been utilised in routine oncological care and there remains only limited evidence to underpin its effectiveness for addressing different components of care across the continuum.

The COVID-19 pandemic necessitated the rapid widespread adoption of telehealth to facilitate enhanced remote healthcare access across many settings including for people with cancer. In Australia, as part of the response to the COVID-19 pandemic, new funding models were introduced to support telehealth consultations with expanded indications. This context afforded a rare opportunity to examine the implementation of and responses to telehealth in cancer health services on a large scale.

Accordingly, there has been increasing clinical commentary on the opportunities to integrate telehealth into routine cancer practice and a particular focus on the practical considerations for effective telehealth delivery into the future. Yet, an empirical understanding of the clinical circumstances and patient populations which may be most appropriate for telehealth models remains scant. As such, the need to establish evidence-based, patient-centred models has been highlighted by cancer services, and there is a clear imperative for both patient- and clinician-reported data to underpin these future models of teleoncology.

This study sought to evaluate perceptions of telehealth in real-world oncological care through a dyadic exploration of matched patient- and clinician-reported outcome data. Our primary objective was to examine patient- and clinician-reported acceptability and explore individual factors which may predict greater suitability for telehealth. This was conducted with a view to understanding the ongoing applicability of telehealth and the role of individual patient, clinical and consultation characteristics underpinning a persons’ appropriateness for telehealth in future models of cancer care.

2 | METHODS

2.1 | Study design and setting

This study utilised a prospective, cross-sectional, exploratory survey design to assess (matched) patient- and clinician-reported perceptions of outpatient telehealth consultations occurring at a metropolitan, tertiary-based cancer centre in Victoria, Australia. The study was guided by the checklist for good practice in the conduct and reporting of survey research described by Kelley. It was conducted as part of a broader mixed-method study, also involving qualitative interviews with a purposive sample of patients and clinicians, the results of which will be reported elsewhere. The study received ethical approval from the St Vincent’s Hospital Human Research Ethics Committee (LRR 096/20)

The study was conducted at a time when strict public health directives were enacted including a period of 15 weeks when stringent lockdown measures were enforced in the state of Victoria, Australia. During this lockdown, there were marked limitations on leaving the house, but attendance at medical appointments was permitted.

2.2 | Description of the telehealth model

We adopted the definition of ‘telehealth’, to include all healthcare delivered ‘at a distance’, both via video and on the telephone, reflecting a person(or patient)-centred, as opposed to a technology-driven approach. In-person hospital attendance for the purposes of day administration of IV systemic anti-cancer therapy by cancer nurse specialists, radiotherapy, examinations or admission as required continued alongside telehealth consultations, with patients separately reviewed by their medical oncologists via telehealth wherever possible even if attending for treatment. All surveillance, treatment reviews and oversight of oral treatment modalities were primarily managed with telehealth.

2.3 | Data collection

2.3.1 | Procedures

All medical oncological consultations conducted by telehealth and occurring between 24 July 2020 and 11 February 2021 were identified from hospital clinics, and those patients meeting study eligibility were identified by the clinician. Patients were eligible if they were (1) receiving medical oncology cancer care at the hospital, (2) participating in a telehealth consultation and (3) able to understand spoken English without the aid of an interpreter. Patients who had participated in the study within the previous 3 months were not-approached for subsequent inclusion.

Following completion of clinician-reported measures at the time of telehealth consultation, patients were approached for participation within 1 week through phone or email by a member of the research team, independent
from their treating team. Those who opted in were provided with the survey, administered by email or via post for those unable to complete it online. All study data were collected and managed using REDCap (Research Electronic Data Capture), a secure, web-based software platform hosted at the University of Melbourne.\(^{13}\) Treating oncologists and patients (separately) completed the outcome measures, providing matched dyadic data through a uniquely generated code. All responses were de-identified and personal data were not available to the researchers.

**2.3.2 | Covariates**

Demographic characteristics (patient-reported): postcode, gender, country of birth, indigeneity, language spoken at home, regionality of home residence, relative socio-economic disadvantage, reported in quintiles, with higher scores representing the lowest disadvantage (i.e. high socio-economic status).\(^ {14}\)

Clinical characteristics (clinician-reported): primary tumour stream, disease stage (Stages I–III/IV), performance status \([\text{Australian-modified Karnofsky Performance Status (AKPS)}]\), \(^ {15}\) current oncological therapies.

Consultation characteristics (patient- and clinician-reported): type of oncological consultation, tasks undertaken during the consultation, mode of delivery of consultation \((\text{audio} \pm \text{visual})\), telehealth platform used, clinician cited reasons for use of telehealth, time spent during the consultation, time spent after the consultation relative to usual care, others present at the time of consultation \((\text{interpreter, family member, other health professional})\).

Clinician characteristics: Clinician-reported familiarity with patient, clinician level of experience \((\text{advanced trainee vs oncologist})\), clinician-rated preference for the delivery of the telehealth consultation.

**2.3.3 | Outcome measures**

Utility of telehealth: Patient perceptions of telehealth technology were assessed using the Telehealth Usability Questionnaire \((\text{TUQ})\), a 21-item patient-reported outcome measure capturing five domains of usability on a 7-point Likert scale: usefulness, ease of use, effectiveness, reliability and satisfaction.\(^ {16}\) We reported mean \((\text{SD})\) scores for each item and a summary score relevant to each domain, with higher values representing more favourable views. The TUQ is the psychometrically robust validated measure, with strong content validity and internal consistency.\(^ {16,17}\)

Acceptability: Patient- and clinician-reported acceptability of telehealth was \((\text{independently})\) assessed using a 5-point Likert scale, where \(1 = \text{very unacceptable}\), \(2 = \text{unacceptable}\), \(3 = \text{neutral or undecided}\), \(4 = \text{acceptable}\) and \(5 = \text{very acceptable}\). From these data, responses of 4 or 5 were collapsed to generate a binary score indicating a positive rating of ‘acceptability’.

**2.4 | Data analyses**

Descriptive statistics were used to summarise the exploratory demographic, clinical and outcome variables of interest. Continuous variables were expressed as mean \((\text{SD})\) or median with interquartile range \((\text{IQR})\) and categorical variables as number \((\text{percentage})\). We assessed the relationship between a series of individual patient demographic, clinical, consultation and clinician characteristics with telehealth acceptability using univariate analyses reporting odds ratios, 95% confidence intervals and \(p\) values. Separate models were run for patient- and clinician-reported outcomes. As there were multiple factors of potential significance relating to clinician views of acceptability, these were also assessed with a multivariate logistic regression model. Consistent with the exploratory aims of this study, no missing was imputed and an alpha of \(<0.05\) was considered statistically significant. All analyses were performed using Stata version 15.1 \((\text{Stata Corp, College Station, Texas, United States of America})\).

**3 | RESULTS**

**3.1 | Description of study population**

During the study timeframe, there were 1155 telehealth consultations undertaken and 763 identified as potentially eligible, representing 66% of all medical oncology consultations occurring at the cancer centre. Of these, 380 clinician-reported surveys were completed \((50\% \text{ response rate})\), and from these, 155 \((\text{matched})\) patient-reported surveys \((41\% \text{ response rate})\) were returned \((\text{Figure 1})\).

Patient participants included in the study population were a median age of 66 years \((\text{IQR 54, 73})\), predominantly female \((57\%)\), and Australian-born \((58\%)\) \((\text{Table 1})\). A large minority spoke a language other than English at home \((27\%)\) and resided outside a metropolitan area \((19\%)\). Breast \((32\%)\) and gastrointestinal \((27\%)\) tumour streams were the most commonly included malignancies. Just less than half of patients had stage IV disease \((46\%)\), and 83% had a performance status above 70 indicating that they could provide self-care but not carry out...
a normal activity or an active work. At the time of consultation, patients were most commonly undergoing disease surveillance (45%), receiving hormone treatment (21%) or systemic anti-cancer therapy—either intravenously (16%) or orally (13%).

3.2 | Description of telehealth consultations

Most telehealth consultations occurred by telephone with audio connection only (62%), with 38% accessing video and audio through the endorsed health service platform (Table 1). The median time spent during the consultation was 15 min, with 72% of clinicians rating the time spent after the consultation as ‘about the same’ relative to usual care. In 40% of consultations, a family member or carer was also present. Among the common reasons for use of telehealth cited by clinicians included because of ‘health service policy’ (90%), rather than, for example patient preference (25%) or distance (17%) factors. The most frequent type of oncological consultations as described by clinicians were treatment reviews (44%) and surveillance (31%) and mostly categorised by tasks of routine care (84%) as opposed to a ‘breaking bad news’ type discussions such as conveying a worse prognosis (3%) or stopping treatment (1%).

3.3 | Perceptions of telehealth

Overall, patient perceptions of telehealth were very positive (Table 2), with high mean (SD) scores reported across all domains, including usefulness, 5.81 (1.27); ease of use, 5.85 (1.35); effectiveness, 5.80 (1.41); reliability, 4.37 (1.89); and satisfaction, 5.71 (1.48). Across all domains, those who received care via the telehealth platform with a visual link to the doctor reported more favourable experiences with significantly higher mean (SD) scores compared to those who received care via the telephone limited to audio only (Table 2, \( p < 0.05 \)).

Across all telehealth consultations, the preferred mode of delivery related to the specific interaction as rated by the treating clinician, in order to preference, was telehealth (audio + video link) 48%, in-person (41%) and telehealth (audio only) 11%.

3.4 | Acceptability of the telehealth consultation

Overall, patients reported high acceptability with the telehealth consultation, with 144 (93%) reporting telehealth was ‘at least somewhat’ or ‘very’ acceptable as a model of receiving their care (Table 3). Clinicians
**TABLE 1** Characteristics of participating patients (n = 155)

| Demographic characteristics |  |
|-----------------------------|--|
| Age (years), median (IQR)   | 66.00 (54.00–73.00) |
| Gender, n (%)               |  |
| Male                        | 63 (41.4%) |
| Female                      | 89 (58.6%) |
| Australian-born, n (%)      | 90 (58.1%) |
| Regionality                 | 29 (19.1%) |
| Metropolitan                | 123 (80.9%) |
| Major regional cities       | 3 (2%) |
| Other regional and remote locations | 26 (17.1%) |

| Relative socio-economic disadvantage (SEIFA rank, Quintiles) |  |
|---------------------------------------------------------------|--|
| 1: Highest relative disadvantage (low socio-economic status) | 9 (5.9%) |
| 2                                                             | 16 (10.5%) |
| 3                                                             | 28 (18.4%) |
| 4                                                             | 44 (28.9%) |
| 5: Lowest relative disadvantage (high socio-economic status) | 55 (36.2%) |

| Speaks a language other than English at home, n (%) | 42 (27.1%) |

| Clinician-reported proficiency with English |  |
|---------------------------------------------|--|
| High (e.g. Competent with English)          | 136 (87.7%) |
| Medium (e.g. English a second language, but conversant) | 14 (9.0%) |
| Low (e.g. interpreter used or needed)       | 5 (3.2%) |

| Clinical characteristics |  |
|--------------------------|--|
| Primary site of cancer, n (%) |  |
| Lung                     | 24 (15.5%) |
| Breast                   | 49 (31.6%) |
| Gastrointestinal         | 41 (26.5%) |
| Urogential               | 10 (6.5%) |
| Other                    | 31 (20.0%) |

| Cancer stage, n (%) |  |
|---------------------|--|
| Stage I–III         | 80 (54.4%) |
| Stage IV            | 67 (45.6%) |

| Performance status AKPS |  |
|-------------------------|--|
| 0–50                    | 7 (4.9%) |
| 51–70                   | 17 (11.8%) |
| 71–100                  | 120 (83.3%) |

| Current therapy, n (%) |  |
|------------------------|--|
| IV systemic anti-cancer therapy | 24 (15.5%) |
| Oral anti-cancer therapy | 20 (12.9%) |
| Hormone therapy        | 33 (21.3%) |
| Radiotherapy           | 2 (1.3%) |

**TABLE 1** (Continued)

| Consultation characteristics |  |
|------------------------------|--|
| Type of consultation, n (%)  |  |
| Diagnosis/first consultation | 7 (4.5%) |
| Treatment review             | 68 (44.2%) |
| Unscheduled adverse event    | 2 (1.3%) |
| Surveillance                 | 48 (31.2%) |
| Disease assessment           | 22 (14.3%) |
| Other                        | 7 (4.5%) |

| Tasks undertaken during the consultation, n (%) |  |
|-----------------------------------------------|--|
| Routine oncology                             | 130 (83.9%) |
| Prognosis—good news discussion               | 3 (1.9%) |
| Prognosis—bad news discussion                 | 4 (2.6%) |
| Treatment decision—new treatment             | 14 (9.0%) |
| Treatment decision—stop treatment            | 2 (1.3%) |
| Other                                         | 2 (1.3%) |

| Mode of telehealth delivery, n (%) |  |
|-----------------------------------|--|
| Audio only (telephone)            | 96 (61.9%) |
| Audio and video                   | 59 (38.1%) |

| Platform used for consultation |  |
|--------------------------------|--|
| Landline                       | 25 (16.1%) |
| Mobile                         | 71 (45.8%) |
| Health service platform (Healthdirect) | 59 (38.1%) |

| Others present at the consultation, n (%) |  |
|-------------------------------------------|--|
| Interpreter                                | 4 (2.6%) |
| Carer or family member                     | 62 (40.0%) |

| Reason(s) for telehealth consultation, n (%) |  |
|----------------------------------------------|--|
| Health service policy                        | 140 (90.3%) |
| Patient at risk for face-face                | 4 (2.6%) |
| Patient too ill to attend in-person          | 1 (0.6%) |
| Patient/carer preference                     | 38 (24.5%) |
| Clinician preference                         | 49 (31.6%) |
| Distance from treatment                      | 27 (17.4%) |
| Telehealth now standard                      | 40 (25.8%) |
| Other                                        | 3 (1.9%) |

| Time spent during consultation in minutes, median (IQR) | 15.00 (10.00–15.00) |

| Time spent after consultation relative to usual care, n (%) |  |
|------------------------------------------------------------|--|
| Less time                                                  | 17 (11.0%) |
| About the same                                             | 111 (72.1%) |
| More time                                                  | 26 (16.9%) |

| Clinician characteristics |  |
|---------------------------|--|
| Clinician-reported familiarity with patient |  |
| Extremely familiar        | 53 (34.2%) |
TABLE 1 (Continued)

| Level of experience       | 41 (26.5%) | 11 (7.1%) | 8 (5.2%) | 42 (27.1%) |
|---------------------------|------------|-----------|----------|------------|
| Consultant                | 63 (40.7%) | 17 (11.0%)| 74 (47.7%)|
| Advanced trainee          |            |           |          |            |

Clinician-rated preferred mode of delivery

| In-person                  | 63 (40.7%)| 17 (11.0%)| 74 (47.7%)|
|----------------------------|-----------|-----------|----------|

*pCould select more than one response.

simply reported that the telehealth consultation was acceptable for a total of 141 (91%) consultations. In general, responses between patients and clinicians were mostly concordant, whereby there were only 17 (11%) cases, where the patient and clinician assessment of the acceptability of telehealth consultation differed. Across all patient demographic, clinical, consultation- and clinician-specific variables analysed (Table 4), several factors were independently associated with the clinician’s views of whether the telehealth consultation was acceptable. Clinicians were less likely to rate telehealth as acceptable when the patient was of older age (OR 0.93, 95% CI: 0.88–0.98, p = 0.005), there was an interpreter present for the consultation (OR 0.08, 95% CI: 0.01–0.62, p = 0.01); there was a family member present for the consultation (OR 0.16, 95% CI: 0.04–0.58, p = 0.006) and were more likely to rate telehealth as acceptable when the patient had a higher performance status (OR 1.04, 95% CI: 1.01–1.08, p = 0.01) and when they were more familiar with the patient (OR 6.67, 95% CI: 1.78–25.04, p = 0.005). Assessing these variables in a multivariate logistic regression model, only age (OR 1.06, 95% CI: 0.99–1.13, p = 0.05), familiarity with the patient (OR 8.20, 95% CI: 1.50–45.06, p = 0.02) and performance status (OR 0.04, 95% CI 1.00–1.08, p = 0.04) was significantly associated with clinician-reported acceptability.

There were fewer factors that independently predicted whether patients found the telehealth consultation acceptable in receiving care (Table 4). Patients were less likely to rate telehealth as acceptable when there was an interpreter present for the consultation (OR 0.06, 95% CI: 0.008–0.51, p = 0.009) and more likely to rate it as acceptable when they had stage I–III disease compared to stage IV (OR 5.29 95% CI: 1.08–25.82, p = 0.04).

4 | DISCUSSION

This study is among the first internationally to report matched patient- and clinician-reported data on the acceptability of telehealth consultations occurring in real-world oncological care, providing novel data which bring together perspectives on telehealth both from those giving and receiving care. The results support some earlier studies suggesting that overall telehealth is perceived—by patients and their clinicians—an as acceptable mode of cancer care delivery. Building on this understanding, this study has additionally highlighted a series of factors that may be important to consider as cancer services integrate telehealth in future models of cancer care.

Our findings of matched clinician- and patient-reported data revealed that while patients and their clinicians reported high overall levels of acceptability in this context and mostly concordant views, there was a minority of patients for whom delivery of care via telehealth was not preferred. We found a series of factors specific to the patient’s individual socio-demographic and clinical situation that was associated with reduced acceptability.

Those factors of the greatest importance were—from a clinician perspective: their familiarity with the patient, the patient’s age, and their performance status; and from a patient perspective: their disease stage and requirement for an interpreter.

Our findings raise several important implications for future models of telehealth, with the potential for this mode of delivery of cancer care to be considered less optimal for patients with higher complexity of need. Most notably, this included those with metastatic cancer who may have a poorer prognosis and changing health status, those who are not well known to the treating clinician, or those who identify to have additional language or technology barriers that may impede the quality of the relationship necessary for clinicians to feel confident in delivering care remotely. Future models of delivering cancer care via telehealth may benefit from considering the development of a triage process, which considers these factors, among other individual preferences for in-person care, to determine who receives telehealth as part of routine care with perspectives of both patients and clinicians considered. These models will also require ongoing evaluation, including a much-needed longitudinal perspective, which links patient- and clinician-reported acceptability data to other safety, efficacy and health outcome data, which to date remains largely unreported.

The existing evidence around telehealth in oncological care during the pandemic, primarily limited to scoping studies including clinical commentaries and specific populations describing their perceptions of telehealth via service-specific surveys, has broadly conveyed a
A less nuanced perspective of delivering cancer care via telehealth. These studies have tended to emphasise the potential benefits of telehealth, such as issues related to cost, choice and convenience, particularly when accessed by people in rural and remote areas. A study of 74 breast and gynaecological patients attending a single institution in New York reported that 92% of patients were satisfied with the use of telehealth services, with

| TABLE 2 Perceptions of utility of telehealth (TUQ) |
|---------------------------------------------------|
| All participants | Audio-only group | Visual link group | p valuea |
| N = 155 | Mean (SD) | N = 97 | Mean (SD) | N = 58 | Mean (SD) |
| Usefulness | | | | | |
| Telehealth improves my access to healthcare services. | 154 | 5.81 (1.27) | 96 | 5.63 (1.37) | 58 | 6.09 (1.03) | 0.03 |
| Telehealth saves me time travelling to a hospital or specialist clinic. | 148 | 5.52 (1.76) | 91 | 5.25 (1.87) | 57 | 5.95 (1.48) | 0.019 |
| Telehealth provides for my healthcare need. | 150 | 6.39 (1.13) | 95 | 6.25 (1.25) | 55 | 6.62 (0.83) | 0.056 |

Ease of use and learnability | | | | | |
| It was simple to use this system. | 152 | 5.85 (1.35) | 95 | 5.61 (1.53) | 57 | 6.24 (0.85) | 0.005 |
| It was easy to learn to use the system. | 146 | 6.12 (1.38) | 92 | 5.96 (1.56) | 54 | 6.39 (0.96) | 0.068 |
| I believe I could become productive quickly using this system | 140 | 6.03 (1.50) | 86 | 5.79 (1.67) | 54 | 6.41 (1.09) | 0.018 |
| The way I interact with this system is pleasant. | 141 | 5.49 (1.77) | 86 | 5.10 (1.95) | 55 | 6.09 (1.25) | 0.001 |
| I like using the system. | 150 | 5.82 (1.49) | 93 | 5.58 (1.62) | 57 | 6.21 (1.15) | 0.011 |
| The system is simple and easy to understand. | 151 | 5.58 (1.76) | 94 | 5.31 (1.93) | 57 | 6.04 (1.32) | 0.013 |
| This system is able to do everything I would want it to be able to do. | 145 | 6.03 (1.35) | 89 | 5.81 (1.54) | 56 | 6.38 (0.86) | 0.013 |

Effectiveness | | | | | |
| I can easily talk to the clinician using the telehealth system. | 154 | 5.80 (1.41) | 96 | 5.60 (1.57) | 58 | 6.13 (1.00) | 0.022 |
| I can hear the clinician clearly using the telehealth system. | 153 | 6.09 (1.45) | 95 | 5.86 (1.62) | 58 | 6.47 (1.01) | 0.012 |
| I felt I was able to express myself effectively. | 151 | 6.19 (1.25) | 93 | 6.14 (1.31) | 58 | 6.26 (1.16) | 0.57 |

Reliability | | | | | |
| I think the visits provided over the telehealth system are the same as in-person | 154 | 4.37 (1.89) | 96 | 3.87 (1.89) | 58 | 5.20 (1.57) | <0.001 |
| Whenever I made a mistake using the system, I could recover easily and quickly. | 154 | 4.05 (2.11) | 96 | 3.59 (2.09) | 58 | 4.81 (1.93) | <0.001 |

Satisfaction and future use | | | | | |
| I feel comfortable communicating with the clinician using the telehealth system. | 154 | 5.71 (1.48) | 96 | 5.40 (1.68) | 58 | 6.22 (0.87) | <0.001 |
| Telehealth is an acceptable way to receive healthcare services. | 153 | 5.41 (1.74) | 95 | 5.05 (1.96) | 58 | 5.98 (1.08) | 0.001 |
| I would use telehealth services again. | 152 | 5.90 (1.51) | 95 | 5.63 (1.70) | 57 | 6.35 (1.01) | 0.004 |
| Overall, I am satisfied with this telehealth system. | 153 | 5.72 (1.66) | 95 | 5.44 (1.84) | 58 | 6.17 (1.17) | 0.008 |

aScores range from 1 to 7 for each question on the TUQ. Mean scores were compared between groups using a two-sided t test.
most patients indicating it saved them time (92%), and increased their access to care (73%). Another mixed cancer population attending a single institution in Houston similarly reported 92.6% were satisfied with telehealth video visits, with those who declined telehealth as an alternative to in-person visits more likely to be older and live in lower-income areas, and less likely to have insurance \( (p = 0.0001) \). Other studies again have highlighted that greater satisfaction with telehealth over physical encounters may depend on the nature of the tasks being undertaken in care, with telehealth being well suited, for example to those undergoing surveillance after active oncologic treatment.\textsuperscript{21}

It is important to note the community context within which this study was undertaken. While in

| TABLE 3 | Acceptability of telehealth consultation—patient and clinician responses \((n = 155)\) |
|---------|---------------------------------------------------------------|
| Patient-reported response | Disagree | Agree | Total |
| Disagree | 2 | 9\textsuperscript{a} | 11 (7) |
| Agree | 12\textsuperscript{a} | 132 | 144 (93) |
| Total | 14 (9%) | 141 (91%) | 155 (100) |

\textsuperscript{a}Discordant views.

| TABLE 4 | Univariate factors associated with patient- and clinician-reported acceptability of telehealth \((n = 155)\) |
|---------|---------------------------------------------------------------|
| Predictor | Patient-reported acceptability | Clinician-reported acceptability |
| | OR | \( p \) value \( 95\% \) CI | OR | \( p \) value \( 95\% \) CI |
| Age\textsuperscript{*} | 0.975 | 0.307 | 0.929 | 1.023 | 0.93 | 0.005 | 0.884 | 0.978 |
| Male | 0.565 | 0.365 | 0.165 | 1.942 | 0.683 | 0.497 | 0.227 | 2.054 |
| Born in Australia | 1.167 | 0.806 | 0.34 | 4.00 | 1.431 | 0.523 | 0.476 | 4.299 |
| Language other than English | 0.627 | 0.476 | 0.174 | 2.264 | 0.64 | 0.45 | 0.202 | 2.034 |
| Interpreter present\textsuperscript{a} | 0.064 | 0.009 | 0.008 | 0.511 | 0.08 | 0.016 | 0.01 | 0.622 |
| Regional home residence | 2.48 | 0.396 | 0.304 | 20.171 | 1.459 | 0.634 | 0.308 | 6.91 |
| Relative socio-economic disadvantage\textsuperscript{a} | 1.19 | 0.488 | 0.733 | 1.919 | 0.896 | 0.651 | 0.556 | 1.445 |
| First telehealth appointment | 2.074 | 0.296 | 0.529 | 8.139 | 0.72 | 0.557 | 0.24 | 2.161 |
| Family member present\textsuperscript{a} | 0.786 | 0.702 | 0.229 | 2.698 | 0.155 | 0.006 | 0.041 | 0.58 |
| Clinician familiarity with patient\textsuperscript{a} | 1.942 | 0.292 | 0.566 | 6.667 | 6.673 | 0.005 | 1.778 | 25.041 |
| Audio and visual telehealth | 1.086 | 0.899 | 0.304 | 3.885 | 1.607 | 0.442 | 0.48 | 5.383 |
| Stage I–III disease\textsuperscript{a} | 5.288 | 0.04 | 1.083 | 25.828 | 0.726 | 0.591 | 0.226 | 2.333 |
| Performance Status\textsuperscript{a} | 1.033 | 0.074 | 0.997 | 1.07 | 1.043 | 0.01 | 1.01 | 1.078 |
| Routine appointment | 0.5 | 0.518 | 0.061 | 4.091 | 1.475 | 0.574 | 0.38 | 5.72 |
| Surveillance appointment | 1.224 | 0.773 | 0.31 | 4.833 | 1.146 | 0.826 | 0.341 | 3.855 |
| Time spent during consultation | 0.98 | 0.734 | 0.871 | 1.103 | 0.977 | 0.665 | 0.879 | 1.086 |

Bold value indicates the statistical significance of \( p < 0.05 \).

\textsuperscript{a} SEIFA rank.

\* \( p < 0.05 \).

Australia, COVID-19 case numbers have remained low, there has been heightened awareness by both patients and clinicians of the importance of minimising opportunities for community transmission including through hospital attendances. Such awareness would have influenced survey responses, and this context must therefore be considered in any future service development. A recent survey revealed that the majority (64%) of the small number of cancer physician respondents preferred in-person visits overall and believed that virtual consultations did not provide comparable care.\textsuperscript{10} Similarly, there is some survey data from small cohorts of people with cancer to suggest that if given a choice, most patients (68%) prefer in-person visits over telemedicine.\textsuperscript{22} Yet, other studies
present contrasting views reporting most patients (76.5%) prefer video-consulting and define it as better than or comparable to an in-person visit. Given the heterogeneity of findings emerging, it is possible that the patient- and physician-perceived threshold for balancing preference for telehealth versus in-person consultations has and will continue to shift with the community caseload of COVID-19 (or similar) at the time.

Despite our study providing a novel dyadic patient and clinician perspective on the acceptability of telehealth, we acknowledge several limitations which are important to consider in the planning of future studies. Although using a validated outcome measure to assess perceptions of telehealth over an exclusively purpose-built survey, we have not assessed long-term health outcomes in this study population, which would require many years of follow-up. Like many existing studies, our sample may have inherent biases related to possible self-selection for participation by those of higher socio-economic advantage and with more positive experiences. Similarly, our results limited to patients receiving care from clinicians at a single cancer centre require external validation.

In conclusion, this study provided novel data on the acceptability of telehealth for the delivery of cancer care, bringing together the dual perspectives of patients and their clinicians. While telehealth was found to be broadly acceptable to patients and their clinicians, our results also highlighted a more nuanced set of individual factors specific to the patient’s individual socio-demographic and clinical situation to be important. Alongside a growing heterogeneous picture emerging across the evidence base, our findings support a need to consider the patients’ level of complexity when triaging which patients may be suited to telehealth. These patient-specific factors may be important considerations in future models of telehealth cancer services, including beyond the pandemic.

ACKNOWLEDGEMENTS
The authors would like to thank the participating patients and their oncology clinicians who voluntarily gave their time to complete outcome measures and contribute to the outcomes of this work.

AUTHOR CONTRIBUTION
AC was responsible for oversight of all aspects of conduct and reporting of the study. LP and AC had access to the data and OW led the analyses in consultation with AC. All authors contributed to the protocol development, clinical interpretation and write up of the results.

CONFlict of interest
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

ETHICS STATEMENT
The study received ethical approval from the St Vincent’s Hospital Human Research Ethics Committee (LRR 096/20). All participants provided written informed consent.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Jennifer Philip https://orcid.org/0000-0002-3312-0645

REFERENCES
1. Clinical Oncology Society of Australia (COSA) Teleoncology Guidelines Working Group. Clinical practice guidelines for teleoncology. Cancer Council Australia; 2016 [cited 9 Mar 2021]. https://wiki.cancer.org.au/australia/Guidelines:COSA:Teleoncology/Summary_of_recommendations.
2. Sirintrupun SJ, Lopez AM. Telemedicine in cancer care. Am Soc Clin Oncol Educ Book. 2018;38:540-545.
3. American Society of Clinical Oncology (ASCO). ASCO special report: a guide to cancer care delivery during the COVID-19 pandemic 2020. https://www.asco.org/sites/new-www.asco.org/files/content-files/2020-ASCO-Guide-Cancer-COVID-19.pdf
4. MBS Online Australian Government Department of Health 2012. http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/connectinghealthservices-patients-QA
5. Health AGDo. COVID-19 temporary MBS telehealth services. 2020. http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Factsheet-TempBB
6. Wong ZW, Cross HL. Telehealth in cancer care during the COVID-19 pandemic. Med J Aust. 2020;213(5):237.e1.
7. Burbury K, Wong ZW, Yip D, et al. Telehealth in cancer care: during and beyond the COVID-19 pandemic. Intern Med J. 2021;51(1):125-133.
8. Thiessen M, Soriano AM, Loewen HJ, Decker KM. Impact of telemedicine use by oncology physicians on the patient and informal caregiver experience of receiving care: protocol for a scoping review in the context of COVID-19. JMIR Res Proto. 2020;9(12):e25501.
9. Darcourt JG, Aparicio K, Dorsey PM, et al. Analysis of the implementation of telehealth visits for Care of Patients with Cancer in Houston during the COVID-19 pandemic. JCO Oncol Pract. 2021;17(1):e36-e43.
10. Wehrle CJ, Lee SW, Devarakonda AK, Arora TK. Patient and physician attitudes toward telemedicine in cancer clinics following the COVID-19 pandemic. JCO Clin Cancer Inform. 2021;5:394-400.
11. Kelley K, Clark B, Brown V, Sitzia J. Good practice in the conduct and reporting of survey research. *Int J Qual Health Care*. 2003;15(3):261-266.

12. Wootton R. Telemedicine: fad or future. *Lancet*. 1995;345(8942):73-74.

13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-381.

14. Australian Bureau of Statistics. Census of population and housing: socio-economic indexes for areas (SEIFA) Australia (cat. no. 2033.0.55.001). Canberra 2016. Updated 27 Mar 2018. https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/2033.0.55.001Main+Features12016?OpenDocument

15. Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC. The Australia-modified Karnofsky performance status (AKPS) scale: a revised scale for contemporary palliative care clinical practice. *BMC Palliat Care*. 2005;4(1):7.

16. Parmanto B, Lewis AN Jr, Graham KM, Bertole MH. Development of the telehealth usability questionnaire (TUQ). *Int J Telerehabilitat*. 2016;8(1):3-10.

17. Langbecker D, Caffery LJ, Gillespie N, Smith AC. Using survey methods in telehealth research: a practical guide. *J Telemed Telecare*. 2017;23(9):770-779.

18. Fisk M, Livingstone A, Pit SW. Telehealth in the context of COVID-19: changing perspectives in Australia, the United Kingdom, and the United States. *J Med Internet Res*. 2020;22(6):e19264.

19. Thaker DA, Monypenny R, Oliver I, Sabesan S. Cost savings from a telemedicine model of care in northern Queensland. *Australia Med J Aust*. 2013;199(6):414-417.

20. Zimmerman BS, Seidman D, Berger N, et al. Patient perception of telehealth Services for Breast and Gynecologic Oncology Care during the COVID-19 pandemic: a single center survey-based study. *J Breast Cancer*. 2020;23(5):542-552.

21. Hasson SF, Waissengrin B, Shachar E, et al. Rapid implementation of telemedicine during the COVID-19 pandemic: perspectives and preferences of patients with cancer. *Oncoologist*. 2021;26(4):e679-e685.

22. Fassas S, Cummings E, Sykes KJ, Bur AM, Shnayder Y, Kakarala K. Telemedicine for head and neck cancer surveillance in the COVID-19 era: promise and pitfalls. *Head Neck*. 2021;43(6):1872-1880.

23. Pardolesi A, Gherzi L, Pastorino U. Telemedicine for management of patients with lung cancer during COVID-19 in an Italian cancer institute: SmartDoc project. *Tumori*. 2021;3008916211012760.

---

**How to cite this article:** Collins A, McLachlan S-A, Pasanen L, Wawryk O, Philip J. Perceptions of telehealth in real-world oncological care: An exploration of matched patient- and clinician-reported acceptability data from an Australian cancer centre. *Cancer Med*. 2022;11(17):3342–3351. doi: [10.1002/cam4.4700](https://doi.org/10.1002/cam4.4700)